Pharmaceuticals, Biotechnology and Life Sciences
ViiV Healthcare on Thursday said it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United…
ViiV Healthcare on Thursday announced the start of HPTN 084,a phase III study to evaluate long-acting cabotegravir for the prevention of…
ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).
ViiV Healthcare, a global specialist HIV company with GSK (GlaxoSmithKline), Pfizer Inc. and Shionogi Limited as shareholders, announced on Tuesday that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks.